Skip to content

NT-proBNP and Troponin I in Dengue Children

NT-proBNP and Troponin I in Children With Dengue Hemorrhagic Shock: a Longitudinal Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04837430
Enrollment
90
Registered
2021-04-08
Start date
2021-04-02
Completion date
2023-12-31
Last updated
2023-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Only, Dengue Shock Syndrome

Keywords

NT-proBNP, Troponin I, Dengue children, Cardiac enzyme

Brief summary

To discribe concentration of NT-proBNP and Troponin I in Dengue hemorrhagic shock children, in correlation between concentration of NT-proBNP and troponin I with total fluid admission, respiratory support, using inotrope and vasopressor using.

Detailed description

Treatment of children with Dengue hemorrhagic shock syndrome (DSS) is challenge, especially in cases with hypotensive shock, profound shock or whom do not have a response to initial crystalloid therapy. Currently, treatment of DSS remains almost supportive, with particular emphasis on careful fluid management. However, fluid overload is a common complication of this treatment, lead to many difficulties in management of severe Dengue children, accompany with morbidity and mortality. Diagnosis of fluid overload mostly based on clinical features and chest X-ray or ultrasound. Until now, no biomarker are widely using for diagnosis of fluid overload in clinical. NT-proBNP is secreted when stretching the wall of the cardiac muscle. This may a suitable biomarker to discover the fluid overload state in children with DSS. Troponin I is a biomarker of cardiac muscle damage.

Interventions

None listed

Sponsors

Le Phuoc Truyen
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Dengue shock children who admitted to ICU

Exclusion criteria

* Excluding the cases of children with cardiovascular disease, hyperthyroidism, taking drugs such as insulin, steroid, estrogen, growth hormone, thyroid hormone

Design outcomes

Primary

MeasureTime frameDescription
Concentration of NT-proBNP10 daysConcentration of NT-proBNP in Children with Dengue hemorrhagic shock and severe shock
Concentration of Troponin I10 daysConcentration of Troponin I in Children with Dengue hemorrhagic shock and severe shock

Secondary

MeasureTime frameDescription
Rate of abnormal laboratory exam14 dayselectrolyte, arterial blood gas, lactate
Cut-off value of NT-proBNP for fluid overload14 daysCut-off value of NT-proBNP for pulmonary edema
Correlation between concentration of NT-proBNP14 daysCorrelation between concentration of NT-proBNP with total fluid admission, respiratory support, using inotrope and vasopressor using
Rate of abnormal liver, kidney, hematology laboratory exam14 daysAST, ALT, ure, creatinin, PLT, PT, aPTT, Fibrinogen
Rate of NS1 Dengue10 daysPositive
Rate of MAC ELISA IgM Dengue14 daysPositive
Rate of complications14 daysPulmonary edema
Rate of respiratory support14 daysCannula, NCPAP, Intubation
Rate of clinical manifestations14 daysRate of clinical manifestations: fever, abdominal pain, petechia, hematomegaly
Rate of mode of ventilation14 daysPC, IP, PEEP, FiO2, VT
Total fluid administration14 daysml/kg/d
Time for IV fluid administration14 dayshours
Rate and kind of cephalosporin using14 days3rd generation cephalosporin
Rate and kind of Carbapenem using14 daysCarbapenem
Rate and kind of Vancomycin using14 daysVancomycin
Rate of intraperitoneal fluid drainage14 daysPositive
Rate of CRRT14 daysPositive
Rate of intubation14 daysPositive
Correlation between concentration of Troponin I14 daysCorrelation between concentration of Troponin I total fluid admission, respiratory support, using inotrope and vasopressor using

Countries

Vietnam

Contacts

Primary ContactLe P. Truyen, MD
dr.letruyen@ump.edu.vn+84 903640025
Backup ContactPhung Nguyen, MD
nguyenphung@ump.edu.vn84 989043858

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026